{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:13:50Z","timestamp":1793106830724,"version":"4.5.0"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"\n Importance<\/jats:title>\n Nasopharyngeal carcinoma (NPC) is a major health concern in Asia, and treatment options for recurrent or metastatic disease are limited. Immunotherapy plus chemotherapy has shown promise, but long-term data are needed to guide first-line treatment.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the 3-year efficacy and safety of tislelizumab plus chemotherapy vs placebo plus chemotherapy in participants with recurrent or metastatic NPC and explore potential biomarkers of treatment response.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n The RATIONALE-309 trial was a double-blind, placebo-controlled phase 3 randomized clinical trial conducted in Asia from April 2019 to December 2023. Treatment-naive adults with histologically or cytologically confirmed recurrent or metastatic NPC were included. Data were analyzed from December 2023 to January 2024.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomized 1:1 to receive tislelizumab, 200 mg, intravenously or placebo every 3 weeks, both with gemcitabine and cisplatin for 4 to 6 cycles. Participants in the placebo arm could cross over to tislelizumab monotherapy at disease progression.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was progression-free survival (PFS) assessed by an independent review committee. The primary hypothesis (PFS superiority for tislelizumab vs placebo) was specified in the protocol prior to data collection. Secondary end points included overall survival (OS), PFS after next-line therapy, and safety.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 263 included participants, 206 (78.3%) were male, and the median (range) age was 50 (23-74) years; the median (range) follow-up was 27.5 (0.1-53.0) months. A total of 131 were randomized to the tislelizumab group and 132 to the placebo group. Tislelizumab plus chemotherapy demonstrated improved PFS vs placebo plus chemotherapy (median PFS, 9.6 months [95% CI, 7.6-11.6] vs 7.4 months [95% CI, 5.6-7.6]; hazard ratio [HR], 0.53; 95% CI, 0.39-0.71). The median OS was 45.3 months (95% CI, 33.4 to not estimable) vs 31.8 months (95% CI, 25.0 to not estimable), respectively (HR, 0.73; 95% CI, 0.51-1.05). Rank-preserving structural failure time analysis (HR, 0.56; 95% CI, 0.27-1.19) and 2-stage crossover-adjusted analysis (HR, 0.62; 95% CI, 0.40-0.97) showed greater OS benefit. Treatment-emergent adverse events occurred in 133 of 133 participants (100%) in the tislelizumab arm and 129 of 130 participants (99.2%) in the placebo arm, with comparable grade 3 or higher adverse event rates. Immune-mediated adverse events were more frequent with tislelizumab (71 [53.4%] vs 49 [37.7%]) but mostly of grades 1 or 2. High B-cell gene expression was associated with greater OS benefit (HR, 0.41; 95% CI, 0.23-0.74).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this secondary analysis of the RATIONALE-309 randomized clinical trial, after 3 years of follow-up, tislelizumab plus chemotherapy provided sustained PFS and meaningful OS improvement vs placebo plus chemotherapy in recurrent or metastatic NPC, with an acceptable safety profile. Greater benefit was observed in participants with activated immune signatures, especially high B-cell expression.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03924986<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2026.0020","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T16:30:30Z","timestamp":1772123430000},"page":"384","source":"Crossref","is-referenced-by-count":14,"title":["First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer"],"prefix":"10.1001","volume":"12","author":[{"given":"Yunpeng","family":"Yang","sequence":"first","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Jui","family":"Yen","sequence":"additional","affiliation":[{"name":"Department of Oncology, National Cheng Kung University Hospital, College of Medicine, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianji","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fujian Cancer Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Radiotherapy, Hunan Cancer Hospital, Changsha City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenhong","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology & Head and Neck, The People\u2019s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianyong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology and Department of Radiation Oncology, West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Beijing Cancer Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"He","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaosu","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Centre, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhu","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Guangzhou Traditional Chinese Medicine University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjie","family":"Wu","sequence":"additional","affiliation":[{"name":"Clinical Development, BeOne Medicines Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Yuan","sequence":"additional","affiliation":[{"name":"Clinical Development, BeOne Medicines Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenqi","family":"Chen","sequence":"additional","affiliation":[{"name":"Clinical Development, BeOne Medicines Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Xu","sequence":"additional","affiliation":[{"name":"Clinical Biomarker Science and CDx Development, BeOne Medicines Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Ma","sequence":"additional","affiliation":[{"name":"Bioinformatics, BeOne Medicines Ltd, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiangjiin","family":"Leaw","sequence":"additional","affiliation":[{"name":"Clinical Development, BeOne Medicines Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Fang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10445","key":"coi260001r2","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","article-title":"Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.","volume":"403","author":"Liu","year":"2024","journal-title":"Lancet"},{"issue":"16","key":"coi260001r3","doi-asserted-by":"publisher","first-page":"6001","DOI":"10.1200\/JCO.2024.42.16_suppl.6001","article-title":"Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial.","volume":"42","author":"Mai","year":"2024","journal-title":"J Clin Oncol"},{"issue":"18","key":"coi260001r4","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jama.2025.1132","article-title":"Adjuvant PD-1 blockade with camrelizumab for nasopharyngeal carcinoma: the DIPPER randomized clinical trial.","volume":"333","author":"Liang","year":"2025","journal-title":"JAMA"},{"key":"coi260001r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102840","article-title":"Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma.","volume":"131","author":"Cai","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"29","key":"coi260001r6","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1200\/JCO.2015.60.9347","article-title":"Management of nasopharyngeal carcinoma: current practice and future perspective.","volume":"33","author":"Lee","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"coi260001r7","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1001\/jama.2025.13205","article-title":"Toripalimab combination therapy without concurrent cisplatin for nasopharyngeal carcinoma: the DIAMOND randomized clinical trial.","volume":"334","author":"Xu","year":"2025","journal-title":"JAMA"},{"issue":"9","key":"coi260001r8","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1007\/s11864-023-01101-3","article-title":"Recurrent\/metastatic nasopharyngeal carcinoma treatment from present to future: where are we and where are we heading?","volume":"24","author":"Juarez-Vignon Whaley","year":"2023","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"coi260001r9","first-page":"1140","article-title":"Current progress in immunotherapy of nasopharyngeal carcinoma.","volume":"13","author":"Chen","year":"2023","journal-title":"Am J Cancer Res"},{"issue":"36","key":"coi260001r10","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","article-title":"Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study.","volume":"35","author":"Hsu","year":"2017","journal-title":"J Clin Oncol"},{"issue":"14","key":"coi260001r11","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","article-title":"Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic Phase 2 Consortium (NCI-9742).","volume":"36","author":"Ma","year":"2018","journal-title":"J Clin Oncol"},{"issue":"20","key":"coi260001r12","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial.","volume":"330","author":"Mai","year":"2023","journal-title":"JAMA"},{"issue":"8","key":"coi260001r13","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"coi260001r14","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","article-title":"Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309).","volume":"41","author":"Yang","year":"2023","journal-title":"Cancer Cell"},{"issue":"11","key":"coi260001r15","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cac2.12218","article-title":"The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma.","volume":"41","author":"Tang","year":"2021","journal-title":"Cancer Commun (Lond)"},{"issue":"3","key":"coi260001r16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.annonc.2022.11.011","article-title":"ESMO-EURACAN Clinical Practice Guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment of recurrent\/metastatic disease.","volume":"34","author":"Bossi","year":"2023","journal-title":"Ann Oncol"},{"issue":"8","key":"coi260001r19","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1080\/03610929108830654","article-title":"Correcting for non-compliance in randomized trials using rank preserving structural failure time models.","volume":"20","author":"Robins","year":"1991","journal-title":"Commun Stat Theory Methods"},{"issue":"3","key":"coi260001r20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/0272989X13520192","article-title":"Adjusting survival time estimates to account for treatment switching in randomized controlled trials\u2013an economic evaluation context: methods, limitations, and recommendations.","volume":"34","author":"Latimer","year":"2014","journal-title":"Med Decis Making"},{"issue":"1","key":"coi260001r21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12874-019-0709-9","article-title":"Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.","volume":"19","author":"Latimer","year":"2019","journal-title":"BMC Med Res Methodol"},{"issue":"29","key":"coi260001r22","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1200\/JCO.21.00396","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma: final overall survival analysis of GEM20110714 phase III study.","volume":"39","author":"Hong","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10054","key":"coi260001r23","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.","volume":"388","author":"Zhang","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"coi260001r24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000648","article-title":"Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective.","volume":"8","author":"Quinn","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"1","key":"coi260001r25","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy.","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"coi260001r26","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.3390\/curroncol30050355","article-title":"Adverse effects of immune-checkpoint inhibitors: a comprehensive imaging-oriented review.","volume":"30","author":"Mallio","year":"2023","journal-title":"Curr Oncol"},{"key":"coi260001r27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1386381","article-title":"PD-L1 expression as a potential predictor of immune checkpoint inhibitor efficacy and survival in patients with recurrent or metastatic nasopharyngeal cancer: a systematic review and meta-analysis of prospective trials.","volume":"14","author":"Xu","year":"2024","journal-title":"Front Oncol"},{"issue":"17","key":"coi260001r28","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1016\/j.cell.2024.06.038","article-title":"Pan-cancer single-cell dissection reveals phenotypically distinct B cell subtypes.","volume":"187","author":"Yang","year":"2024","journal-title":"Cell"},{"issue":"1","key":"coi260001r29","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/s41467-021-21795-z","article-title":"Comprehensive single-cell sequencing reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of nasopharyngeal carcinoma.","volume":"12","author":"Gong","year":"2021","journal-title":"Nat Commun"},{"key":"coi260001r30","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.101885","article-title":"The role of tertiary lymphoid structure and B cells in nasopharyngeal carcinoma: based on bioinformatics and experimental verification.","volume":"41","author":"Chen","year":"2024","journal-title":"Transl Oncol"},{"issue":"7","key":"coi260001r31","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","article-title":"B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome.","volume":"19","author":"Fridman","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"6576","key":"coi260001r32","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf9419","article-title":"Tertiary lymphoid structures in cancer.","volume":"375","author":"Schumacher","year":"2022","journal-title":"Science"},{"issue":"6","key":"coi260001r33","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41591-023-02369-6","article-title":"The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment.","volume":"29","author":"Lv","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"coi260001r34","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1038\/s41467-021-23379-3","article-title":"Molecular landscape and subtype-specific therapeutic response of nasopharyngeal carcinoma revealed by integrative pharmacogenomics.","volume":"12","author":"Ding","year":"2021","journal-title":"Nat Commun"},{"key":"coi260001r1","unstructured":"World Health Organization. Cancer fact sheet \u2013 nasopharynx. Accessed August 12, 2024. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/4-nasopharynx-fact-sheet.pdf"},{"key":"coi260001r17","unstructured":"European Commission approves TEVIMBRA\u00ae in combination with chemotherapy as a first-line treatment for nasopharyngeal carcinoma. News release. BeOne Medicines; July 10, 2025. Accessed July 24, 2025. https:\/\/ir.beonemedicines.com\/news\/european-commission-approves-tevimbrar-in-combination-with-chemotherapy-as-a-first-line-treatment-for-nasopharyngeal-carcinoma\/3ed59f18-6818-4ab5-8c33-3ce2b78144df"},{"key":"coi260001r18","unstructured":"China NMPA approves tislelizumab for recurrent or metastatic nasopharyngeal cancer. News release. BeOne Medicines; June 10, 2022. Accessed July 24, 2025. https:\/\/sseir.beonemedicines.com\/en\/news\/china-nmpa-approves-tislelizumab-for-recurrent-or-metastatic-nasopharyngeal-cancer\/9900f4cd-c07c-4048-a1ad-0b62f0897c39"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2845508\/jamaoncology_yang_2026_oi_260001_1775759215.12669.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:00:33Z","timestamp":1776351633000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2845508"}},"subtitle":["Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2026.0020","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}